Skip to main content
Erschienen in: Abdominal Radiology 7/2019

12.04.2019 | Review

The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI

verfasst von: Laura Rozenblum, Fatima-Zohra Mokrane, Randy Yeh, Mathieu Sinigaglia, Florent Besson, Romain-David Seban, Cecile N Chougnet, Paul Revel-Mouroz, Binsheng Zhao, Philippe Otal, Lawrence H. Schwartz, Laurent Dercle

Erschienen in: Abdominal Radiology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms that secrete peptides and neuro-amines. pNETs can be sporadic or hereditary, syndromic or non-syndromic with different clinical presentations and prognoses. The role of medical imaging includes locating the tumor, assessing its extent, and evaluating the feasibility of curative surgery or cytoreduction. Pancreatic NETs have very distinctive phenotypes on CT, MRI, and PET. PET have been demonstrated to be very sensitive to detect either well-differentiated pNETs using 68Gallium somatostatin receptor (SSTR) radiotracers, or more aggressive undifferentiated pNETS using 18F-FDG. A comprehensive interpretation of multimodal imaging guides resectability and cytoreduction in pNETs. The imaging phenotype provides information on the differentiation and proliferation of pNETs, as well as the spatial and temporal heterogeneity of tumors with prognostic and therapeutic implications. This review provides a structured approach for standardized reading and reporting of medical imaging studies with a focus on PET and MR techniques. It explains which imaging approach should be used for different subtypes of pNET and what a radiologist should be looking for and reporting when interpreting these studies.
Literatur
3.
Zurück zum Zitat Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT, Participants aoVCC (2016) ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 103 (2):153-171. https://doi.org/10.1159/000443171 CrossRefPubMed Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT, Participants aoVCC (2016) ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 103 (2):153-171. https://​doi.​org/​10.​1159/​000443171 CrossRefPubMed
4.
Zurück zum Zitat Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernández-del Castillo C (2007) Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Archives of Surgery 142 (4):347-354CrossRefPubMed Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernández-del Castillo C (2007) Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Archives of Surgery 142 (4):347-354CrossRefPubMed
5.
Zurück zum Zitat Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino K, Meriden Z, Choti M, Diaz LA, Pawlik TM, Schulick RD, Hruban RH, Edil BH (2014) A single institution’s 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg 259 (2):204-212. https://doi.org/10.1097/sla.0b013e31828f3174 CrossRefPubMed Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino K, Meriden Z, Choti M, Diaz LA, Pawlik TM, Schulick RD, Hruban RH, Edil BH (2014) A single institution’s 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg 259 (2):204-212. https://​doi.​org/​10.​1097/​sla.​0b013e31828f3174​ CrossRefPubMed
11.
Zurück zum Zitat Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Fanti S (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging 44 (9):1588-1601. https://doi.org/10.1007/s00259-017-3728-y CrossRefPubMed Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Fanti S (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging 44 (9):1588-1601. https://​doi.​org/​10.​1007/​s00259-017-3728-y CrossRefPubMed
14.
Zurück zum Zitat Klöppel G, Klimstra DS, Hruban RH, Adsay V, Capella C, Couvelard A, Komminoth P, La Rosa S, Ohike N, Osamura RY, Perren A, Scoazec J-Y, Rindi G (2017) Pancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification. AJSP: Reviews & Reports 22 (5) Klöppel G, Klimstra DS, Hruban RH, Adsay V, Capella C, Couvelard A, Komminoth P, La Rosa S, Ohike N, Osamura RY, Perren A, Scoazec J-Y, Rindi G (2017) Pancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification. AJSP: Reviews & Reports 22 (5)
17.
Zurück zum Zitat Sho S, Court CM, Winograd P, Toste PA, Pisegna JR, Lewis M, Donahue TR, Hines OJ, Reber HA, Dawson DW, Tomlinson JS (2018) A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. https://doi.org/10.1007/s11605-018-4011-7 Sho S, Court CM, Winograd P, Toste PA, Pisegna JR, Lewis M, Donahue TR, Hines OJ, Reber HA, Dawson DW, Tomlinson JS (2018) A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. https://​doi.​org/​10.​1007/​s11605-018-4011-7
18.
Zurück zum Zitat Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec J-Y, Salazar R, Sauvanet A, Kianmanesh R (2012) ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes. Neuroendocrinology 95 (2):98-119. https://doi.org/10.1159/000335591 CrossRefPubMedPubMedCentral Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec J-Y, Salazar R, Sauvanet A, Kianmanesh R (2012) ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes. Neuroendocrinology 95 (2):98-119. https://​doi.​org/​10.​1159/​000335591 CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E (2016) Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 34 (6):588-596. https://doi.org/10.1200/jco.2015.64.0987 CrossRefPubMed Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E (2016) Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 34 (6):588-596. https://​doi.​org/​10.​1200/​jco.​2015.​64.​0987 CrossRefPubMed
20.
21.
Zurück zum Zitat Oberndorfer S (1907) Karzinoide tumoren des dunndarms. Frankfurt Z Path 1:426-432 Oberndorfer S (1907) Karzinoide tumoren des dunndarms. Frankfurt Z Path 1:426-432
22.
Zurück zum Zitat Öberg KE (2010) Gastrointestinal neuroendocrine tumors. Annals of Oncology 21 (suppl_7):vii72-vii80 Öberg KE (2010) Gastrointestinal neuroendocrine tumors. Annals of Oncology 21 (suppl_7):vii72-vii80
25.
Zurück zum Zitat Owen N, Sohaib S, Peppercorn P, Monson J, Grossman A, Besser G, Reznek R (2001) MRI of pancreatic neuroendocrine tumours. The British journal of radiology 74 (886):968-973CrossRefPubMed Owen N, Sohaib S, Peppercorn P, Monson J, Grossman A, Besser G, Reznek R (2001) MRI of pancreatic neuroendocrine tumours. The British journal of radiology 74 (886):968-973CrossRefPubMed
26.
Zurück zum Zitat Kim JH, Eun HW, Kim YJ, Han JK, Choi BI (2013) Staging accuracy of MR for pancreatic neuroendocrine tumor and imaging findings according to the tumor grade. Abdominal imaging 38 (5):1106-1114CrossRefPubMed Kim JH, Eun HW, Kim YJ, Han JK, Choi BI (2013) Staging accuracy of MR for pancreatic neuroendocrine tumor and imaging findings according to the tumor grade. Abdominal imaging 38 (5):1106-1114CrossRefPubMed
27.
Zurück zum Zitat Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135 (5):1469-1492CrossRefPubMed Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135 (5):1469-1492CrossRefPubMed
31.
Zurück zum Zitat Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT (2013) Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 92 (3):135-181. https://doi.org/10.1097/md.0b013e3182954af1 CrossRef Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT (2013) Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 92 (3):135-181. https://​doi.​org/​10.​1097/​md.​0b013e3182954af1​ CrossRef
33.
Zurück zum Zitat Lipinski M, Rydzewska G, Foltyn W, Andrysiak-Mamos E, Baldys-Waligorska A, Bednarczuk T, Blicharz-Dorniak J, Bolanowski M, Boratyn-Nowicka A, Borowska M, Cichocki A, Cwikla JB, Falconi M, Handkiewicz-Junak D, Hubalewska-Dydejczyk A, Jarzab B, Junik R, Kajdaniuk D, Kaminski G, Kolasinska-Cwikla A, Kowalska A, Krol R, Krolicki L, Kunikowska J, Kusnierz K, Lampe P, Lange D, Lewczuk-Myslicka A, Lewinski A, Londzin-Olesik M, Marek B, Nasierowska-Guttmejer A, Nowakowska-Dulawa E, Pilch-Kowalczyk J, Poczkaj K, Rosiek V, Ruchala M, Sieminska L, Sowa-Staszczak A, Starzynska T, Steinhof-Radwanska K, Strzelczyk J, Sworczak K, Syrenicz A, Szawlowski A, Szczepkowski M, Wachula E, Zajecki W, Zemczak A, Zgliczynski W, Kos-Kudla B (2017) Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol 68 (2):138-153. https://doi.org/10.5603/ep.2017.0016 CrossRefPubMed Lipinski M, Rydzewska G, Foltyn W, Andrysiak-Mamos E, Baldys-Waligorska A, Bednarczuk T, Blicharz-Dorniak J, Bolanowski M, Boratyn-Nowicka A, Borowska M, Cichocki A, Cwikla JB, Falconi M, Handkiewicz-Junak D, Hubalewska-Dydejczyk A, Jarzab B, Junik R, Kajdaniuk D, Kaminski G, Kolasinska-Cwikla A, Kowalska A, Krol R, Krolicki L, Kunikowska J, Kusnierz K, Lampe P, Lange D, Lewczuk-Myslicka A, Lewinski A, Londzin-Olesik M, Marek B, Nasierowska-Guttmejer A, Nowakowska-Dulawa E, Pilch-Kowalczyk J, Poczkaj K, Rosiek V, Ruchala M, Sieminska L, Sowa-Staszczak A, Starzynska T, Steinhof-Radwanska K, Strzelczyk J, Sworczak K, Syrenicz A, Szawlowski A, Szczepkowski M, Wachula E, Zajecki W, Zemczak A, Zgliczynski W, Kos-Kudla B (2017) Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol 68 (2):138-153. https://​doi.​org/​10.​5603/​ep.​2017.​0016 CrossRefPubMed
34.
Zurück zum Zitat O’Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, Hyrdel R, Nikou G, Krenning E, Vullierme M-P (2006) Rare functioning pancreatic endocrine tumors. Neuroendocrinology 84 (3):189-195CrossRefPubMed O’Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, Hyrdel R, Nikou G, Krenning E, Vullierme M-P (2006) Rare functioning pancreatic endocrine tumors. Neuroendocrinology 84 (3):189-195CrossRefPubMed
41.
43.
Zurück zum Zitat De Robertis R, Maris B, Cardobi N, Tinazzi Martini P, Gobbo S, Capelli P, Ortolani S, Cingarlini S, Paiella S, Landoni L, Butturini G, Regi P, Scarpa A, Tortora G, D’Onofrio M (2018) Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? Eur Radiol. https://doi.org/10.1007/s00330-017-5236-7 De Robertis R, Maris B, Cardobi N, Tinazzi Martini P, Gobbo S, Capelli P, Ortolani S, Cingarlini S, Paiella S, Landoni L, Butturini G, Regi P, Scarpa A, Tortora G, D’Onofrio M (2018) Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? Eur Radiol. https://​doi.​org/​10.​1007/​s00330-017-5236-7
44.
Zurück zum Zitat Buetow PC, Buck JL, Pantongrag-Brown L, Beck KG, Ros PR, Adair CF (1996) Solid and papillary epithelial neoplasm of the pancreas: imaging-pathologic correlation on 56 cases. Radiology 199 (3):707-711CrossRefPubMed Buetow PC, Buck JL, Pantongrag-Brown L, Beck KG, Ros PR, Adair CF (1996) Solid and papillary epithelial neoplasm of the pancreas: imaging-pathologic correlation on 56 cases. Radiology 199 (3):707-711CrossRefPubMed
45.
46.
Zurück zum Zitat Sureka B, Meena V, Khera PS (2018) Differential diagnosis of pancreatic calcifications. American Journal of Roentgenology 210 (1):W43-W43CrossRefPubMed Sureka B, Meena V, Khera PS (2018) Differential diagnosis of pancreatic calcifications. American Journal of Roentgenology 210 (1):W43-W43CrossRefPubMed
47.
Zurück zum Zitat Javadi S, Menias CO, Korivi BR, Shaaban AM, Patnana M, Alhalabi K, Elsayes KM (2017) Pancreatic calcifications and calcified pancreatic masses: pattern recognition approach on CT. American Journal of Roentgenology 209 (1):77-87CrossRefPubMed Javadi S, Menias CO, Korivi BR, Shaaban AM, Patnana M, Alhalabi K, Elsayes KM (2017) Pancreatic calcifications and calcified pancreatic masses: pattern recognition approach on CT. American Journal of Roentgenology 209 (1):77-87CrossRefPubMed
49.
Zurück zum Zitat Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC (2006) Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47 (3):502-511PubMed Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC (2006) Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47 (3):502-511PubMed
51.
Zurück zum Zitat Reubi JC, Waser B, Friess H, Büchler M, Laissue J (1998) Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 42 (4):546CrossRefPubMedPubMedCentral Reubi JC, Waser B, Friess H, Büchler M, Laissue J (1998) Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 42 (4):546CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Stabin MG, Kooij PP, Bakker WH, Inoue T, Endo K, Coveney J, de Jong R, Minegishi A (1997) Radiation dosimetry for indium-111-pentetreotide. J Nucl Med 38 (12):1919-1922PubMed Stabin MG, Kooij PP, Bakker WH, Inoue T, Endo K, Coveney J, de Jong R, Minegishi A (1997) Radiation dosimetry for indium-111-pentetreotide. J Nucl Med 38 (12):1919-1922PubMed
54.
Zurück zum Zitat Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K (2015) 68 Gallium-and 90 Yttrium-/177 Lutetium:“theranostic twins” for diagnosis and treatment of NETs. Annals of nuclear medicine 29 (1):1-7CrossRefPubMed Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K (2015) 68 Gallium-and 90 Yttrium-/177 Lutetium:“theranostic twins” for diagnosis and treatment of NETs. Annals of nuclear medicine 29 (1):1-7CrossRefPubMed
56.
Zurück zum Zitat Fani M, Nicolas GP, Wild D (2017) Somatostatin receptor antagonists for imaging and therapy. J Nucl Med 58 (Suppl 2):61S-66SCrossRefPubMed Fani M, Nicolas GP, Wild D (2017) Somatostatin receptor antagonists for imaging and therapy. J Nucl Med 58 (Suppl 2):61S-66SCrossRefPubMed
57.
Zurück zum Zitat Kauhanen S, Seppanen M, Nuutila P (2008) Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography. J Clin Oncol 26 (32):5307-5308; author reply 5308-5309. https://doi.org/10.1200/jco.2008.18.8581 Kauhanen S, Seppanen M, Nuutila P (2008) Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography. J Clin Oncol 26 (32):5307-5308; author reply 5308-5309. https://​doi.​org/​10.​1200/​jco.​2008.​18.​8581
62.
Zurück zum Zitat Bucau M, Laurent-Bellue A, Poté N, Hentic O, Cros J, Mikail N, Rebours V, Ruszniewski P, Lebtahi R, Couvelard A (2018) 18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation. Neuroendocrinology 106 (3):274-282CrossRefPubMed Bucau M, Laurent-Bellue A, Poté N, Hentic O, Cros J, Mikail N, Rebours V, Ruszniewski P, Lebtahi R, Couvelard A (2018) 18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation. Neuroendocrinology 106 (3):274-282CrossRefPubMed
63.
Zurück zum Zitat Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, Klever P, Sabri O, Schumpelick V, Buell U (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. European journal of nuclear medicine 24 (6):678-682CrossRefPubMed Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, Klever P, Sabri O, Schumpelick V, Buell U (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. European journal of nuclear medicine 24 (6):678-682CrossRefPubMed
65.
Zurück zum Zitat Sowa-Staszczak A, Pach D, Mikolajczak R, Macke H, Jabrocka-Hybel A, Stefanska A, Tomaszuk M, Janota B, Gilis-Januszewska A, Malecki M, Kaminski G, Kowalska A, Kulig J, Matyja A, Osuch C, Hubalewska-Dydejczyk A (2013) Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 40 (4):524-531. https://doi.org/10.1007/s00259-012-2299-1 CrossRefPubMed Sowa-Staszczak A, Pach D, Mikolajczak R, Macke H, Jabrocka-Hybel A, Stefanska A, Tomaszuk M, Janota B, Gilis-Januszewska A, Malecki M, Kaminski G, Kowalska A, Kulig J, Matyja A, Osuch C, Hubalewska-Dydejczyk A (2013) Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 40 (4):524-531. https://​doi.​org/​10.​1007/​s00259-012-2299-1 CrossRefPubMed
66.
Zurück zum Zitat Sowa-Staszczak A, Trofimiuk-Müldner M, Stefańska A, Tomaszuk M, Buziak-Bereza M, Gilis-Januszewska A, Jabrocka-Hybel A, Głowa B, Małecki M, Bednarczuk T (2016) 99mTc labeled glucagon-like peptide-1-analogue (99mTc-GLP1) scintigraphy in the management of patients with occult insulinoma. PloS one 11 (8):e0160714CrossRefPubMedPubMedCentral Sowa-Staszczak A, Trofimiuk-Müldner M, Stefańska A, Tomaszuk M, Buziak-Bereza M, Gilis-Januszewska A, Jabrocka-Hybel A, Głowa B, Małecki M, Bednarczuk T (2016) 99mTc labeled glucagon-like peptide-1-analogue (99mTc-GLP1) scintigraphy in the management of patients with occult insulinoma. PloS one 11 (8):e0160714CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat Christ E, Wild D, Ederer S, Béhé M, Nicolas G, Caplin ME, Brändle M, Clerici T, Fischli S, Stettler C (2013) Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. The Lancet Diabetes & Endocrinology 1 (2):115-122CrossRef Christ E, Wild D, Ederer S, Béhé M, Nicolas G, Caplin ME, Brändle M, Clerici T, Fischli S, Stettler C (2013) Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. The Lancet Diabetes & Endocrinology 1 (2):115-122CrossRef
68.
Zurück zum Zitat Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P, Norton JA (1991) Insulinomas: localization with selective intraarterial injection of calcium. Radiology 178 (1):237-241CrossRefPubMed Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P, Norton JA (1991) Insulinomas: localization with selective intraarterial injection of calcium. Radiology 178 (1):237-241CrossRefPubMed
69.
Zurück zum Zitat Braatvedt G, Jennison E, Holdaway IM (2014) Comparison of two low-dose calcium infusion schedules for localization of insulinomas by selective pancreatic arterial injection with hepatic venous sampling for insulin. Clinical endocrinology 80 (1):80-84CrossRefPubMed Braatvedt G, Jennison E, Holdaway IM (2014) Comparison of two low-dose calcium infusion schedules for localization of insulinomas by selective pancreatic arterial injection with hepatic venous sampling for insulin. Clinical endocrinology 80 (1):80-84CrossRefPubMed
70.
Zurück zum Zitat Kato M, Doi R, Imamura M, Furutani M, Hosotani R, Shimada Y (1997) Calcium-evoked insulin release from insulinoma cells is mediated via calcium-sensing receptor. Surgery 122 (6):1203-1211 Kato M, Doi R, Imamura M, Furutani M, Hosotani R, Shimada Y (1997) Calcium-evoked insulin release from insulinoma cells is mediated via calcium-sensing receptor. Surgery 122 (6):1203-1211
72.
Zurück zum Zitat Morganstein D, Lewis D, Jackson J, Isla A, Lynn J, Devendra D, Meeran K, Todd J (2009) The role of arterial stimulation and simultaneous venous sampling in addition to cross-sectional imaging for localisation of biochemically proven insulinoma. Eur Radiol 19 (10):2467-2473CrossRefPubMed Morganstein D, Lewis D, Jackson J, Isla A, Lynn J, Devendra D, Meeran K, Todd J (2009) The role of arterial stimulation and simultaneous venous sampling in addition to cross-sectional imaging for localisation of biochemically proven insulinoma. Eur Radiol 19 (10):2467-2473CrossRefPubMed
73.
Zurück zum Zitat Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH (2018) The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma. Abdominal Radiology 43 (2):415-434CrossRefPubMed Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH (2018) The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma. Abdominal Radiology 43 (2):415-434CrossRefPubMed
74.
Zurück zum Zitat Attenberger U, Catana C, Chandarana H, Catalano OA, Friedman K, Schonberg SA, Thrall J, Salvatore M, Rosen BR, Guimaraes AR (2015) Whole-body FDG PET-MR oncologic imaging: pitfalls in clinical interpretation related to inaccurate MR-based attenuation correction. Abdominal Imaging 40 (6):1374-1386. https://doi.org/10.1007/s00261-015-0455-3 CrossRefPubMed Attenberger U, Catana C, Chandarana H, Catalano OA, Friedman K, Schonberg SA, Thrall J, Salvatore M, Rosen BR, Guimaraes AR (2015) Whole-body FDG PET-MR oncologic imaging: pitfalls in clinical interpretation related to inaccurate MR-based attenuation correction. Abdominal Imaging 40 (6):1374-1386. https://​doi.​org/​10.​1007/​s00261-015-0455-3 CrossRefPubMed
75.
Zurück zum Zitat Kamisawa T, Takum K, Anjiki H, Egawa N, Kurata M, Honda G, Tsuruta K (2010) FDG-PET/CT findings of autoimmune pancreatitis. Hepato-gastroenterology 57 (99-100):447-450PubMed Kamisawa T, Takum K, Anjiki H, Egawa N, Kurata M, Honda G, Tsuruta K (2010) FDG-PET/CT findings of autoimmune pancreatitis. Hepato-gastroenterology 57 (99-100):447-450PubMed
83.
Zurück zum Zitat Dercle L, Deandreis D, Terroir M, Leboulleux S, Lumbroso J, Schlumberger M (2016) Evaluation of 124 I PET/CT and 124 I PET/MRI in the management of patients with differentiated thyroid cancer. European journal of nuclear medicine and molecular imaging 43 (6):1006-1010CrossRefPubMed Dercle L, Deandreis D, Terroir M, Leboulleux S, Lumbroso J, Schlumberger M (2016) Evaluation of 124 I PET/CT and 124 I PET/MRI in the management of patients with differentiated thyroid cancer. European journal of nuclear medicine and molecular imaging 43 (6):1006-1010CrossRefPubMed
90.
Zurück zum Zitat Attenberger U, Catana C, Chandarana H, Catalano OA, Friedman K, Schonberg SA, Thrall J, Salvatore M, Rosen BR, Guimaraes AR (2015) Whole-body FDG PET-MR oncologic imaging: pitfalls in clinical interpretation related to inaccurate MR-based attenuation correction. Abdom Imaging 40 (6):1374-1386. https://doi.org/10.1007/s00261-015-0455-3 CrossRefPubMed Attenberger U, Catana C, Chandarana H, Catalano OA, Friedman K, Schonberg SA, Thrall J, Salvatore M, Rosen BR, Guimaraes AR (2015) Whole-body FDG PET-MR oncologic imaging: pitfalls in clinical interpretation related to inaccurate MR-based attenuation correction. Abdom Imaging 40 (6):1374-1386. https://​doi.​org/​10.​1007/​s00261-015-0455-3 CrossRefPubMed
93.
Zurück zum Zitat Dercle L, Lu L, Lichtenstein P, Yang H, Wang D, Zhu J, Wu F, Piessevaux H, Schwartz LH, Zhao B (2017) Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm. JCO Clinical Cancer Informatics (1):1-8. https://doi.org/10.1200/cci.17.00108 CrossRefPubMed Dercle L, Lu L, Lichtenstein P, Yang H, Wang D, Zhu J, Wu F, Piessevaux H, Schwartz LH, Zhao B (2017) Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm. JCO Clinical Cancer Informatics (1):1-8. https://​doi.​org/​10.​1200/​cci.​17.​00108 CrossRefPubMed
94.
Zurück zum Zitat Dercle L, Chisin R, Ammari S, Gillebert Q, Ouali M, Jaudet C, Delord JP, Dierickx L, Zerdoud S, Schlumberger M, Courbon F (2014) Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: Are MRI or F-FDG PET/CT able to provide an accurate prediction of long-term outcome? Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-014-2938-9 Dercle L, Chisin R, Ammari S, Gillebert Q, Ouali M, Jaudet C, Delord JP, Dierickx L, Zerdoud S, Schlumberger M, Courbon F (2014) Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: Are MRI or F-FDG PET/CT able to provide an accurate prediction of long-term outcome? Eur J Nucl Med Mol Imaging. https://​doi.​org/​10.​1007/​s00259-014-2938-9
96.
101.
Zurück zum Zitat De Robertis R, Paiella S, Cardobi N, Landoni L, Tinazzi Martini P, Ortolani S, De Marchi G, Gobbo S, Giardino A, Butturini G, Tortora G, Bassi C, D’Onofrio M (2018) Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay. Abdom Radiol (NY) 43 (3):613-619. https://doi.org/10.1007/s00261-017-1243-z CrossRef De Robertis R, Paiella S, Cardobi N, Landoni L, Tinazzi Martini P, Ortolani S, De Marchi G, Gobbo S, Giardino A, Butturini G, Tortora G, Bassi C, D’Onofrio M (2018) Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay. Abdom Radiol (NY) 43 (3):613-619. https://​doi.​org/​10.​1007/​s00261-017-1243-z CrossRef
102.
Zurück zum Zitat Kulke MH, Anthony LB, Bushnell DL, De Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39 (6):735CrossRefPubMedPubMedCentral Kulke MH, Anthony LB, Bushnell DL, De Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39 (6):735CrossRefPubMedPubMedCentral
103.
Zurück zum Zitat Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O’Connor JM, O’Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme M-P, all other Antibes Consensus Conference p (2017) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology 105 (3):212-244. https://doi.org/10.1159/000471879 CrossRefPubMed Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O’Connor JM, O’Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme M-P, all other Antibes Consensus Conference p (2017) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology 105 (3):212-244. https://​doi.​org/​10.​1159/​000471879 CrossRefPubMed
106.
Zurück zum Zitat Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O’Connor JM, Pauwels S, Kloppel G, Frascati Consensus C, European Neuroendocrine Tumor S (2006) Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84 (3):173-182. https://doi.org/10.1159/000098009 CrossRefPubMed Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O’Connor JM, Pauwels S, Kloppel G, Frascati Consensus C, European Neuroendocrine Tumor S (2006) Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84 (3):173-182. https://​doi.​org/​10.​1159/​000098009 CrossRefPubMed
107.
Zurück zum Zitat Ellison EC, Johnson JA (2009) The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Current problems in surgery 46 (1):13-106CrossRefPubMed Ellison EC, Johnson JA (2009) The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Current problems in surgery 46 (1):13-106CrossRefPubMed
108.
Zurück zum Zitat d’Assignies G, Fina P, Bruno O, Vullierme MP, Tubach F, Paradis V, Sauvanet A, Ruszniewski P, Vilgrain V (2013) High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology 268 (2):390-399. https://doi.org/10.1148/radiol.13121628 CrossRefPubMed d’Assignies G, Fina P, Bruno O, Vullierme MP, Tubach F, Paradis V, Sauvanet A, Ruszniewski P, Vilgrain V (2013) High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology 268 (2):390-399. https://​doi.​org/​10.​1148/​radiol.​13121628 CrossRefPubMed
109.
Zurück zum Zitat Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R, Barcelona Consensus Conference p (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95 (2):157-176. https://doi.org/10.1159/000335597 CrossRefPubMed Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R, Barcelona Consensus Conference p (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95 (2):157-176. https://​doi.​org/​10.​1159/​000335597 CrossRefPubMed
112.
Zurück zum Zitat Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M, Sigal R, Baudin E (2005) Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23 (1):70-78. https://doi.org/10.1200/jco.2005.01.013 CrossRefPubMed Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M, Sigal R, Baudin E (2005) Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23 (1):70-78. https://​doi.​org/​10.​1200/​jco.​2005.​01.​013 CrossRefPubMed
114.
Zurück zum Zitat Eriksson J, Stålberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, Granberg D, Eriksson B, Åkerström G, Hellman P (2008) Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors. World J Surg 32 (5):930-938. https://doi.org/10.1007/s00268-008-9510-3 CrossRefPubMed Eriksson J, Stålberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, Granberg D, Eriksson B, Åkerström G, Hellman P (2008) Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors. World J Surg 32 (5):930-938. https://​doi.​org/​10.​1007/​s00268-008-9510-3 CrossRefPubMed
115.
Zurück zum Zitat de Baere T, Palussiere J, Auperin A, Hakime A, Abdel-Rehim M, Kind M, Dromain C, Ravaud A, Tebboune N, Boige V, Malka D, Lafont C, Ducreux M (2006) Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology 240 (2):587-596. https://doi.org/10.1148/radiol.2402050807 CrossRefPubMed de Baere T, Palussiere J, Auperin A, Hakime A, Abdel-Rehim M, Kind M, Dromain C, Ravaud A, Tebboune N, Boige V, Malka D, Lafont C, Ducreux M (2006) Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology 240 (2):587-596. https://​doi.​org/​10.​1148/​radiol.​2402050807 CrossRefPubMed
116.
Zurück zum Zitat Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P (2015) Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford) 17 (1):29-37. https://doi.org/10.1111/hpb.12326 CrossRef Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P (2015) Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford) 17 (1):29-37. https://​doi.​org/​10.​1111/​hpb.​12326 CrossRef
117.
Zurück zum Zitat Vogl TJ, Gruber T, Naguib NNN, Hammerstingl R, Nour-Eldin N-EA (2009) Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. American Journal of Roentgenology 193 (4):941-947CrossRefPubMed Vogl TJ, Gruber T, Naguib NNN, Hammerstingl R, Nour-Eldin N-EA (2009) Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. American Journal of Roentgenology 193 (4):941-947CrossRefPubMed
Metadaten
Titel
The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI
verfasst von
Laura Rozenblum
Fatima-Zohra Mokrane
Randy Yeh
Mathieu Sinigaglia
Florent Besson
Romain-David Seban
Cecile N Chougnet
Paul Revel-Mouroz
Binsheng Zhao
Philippe Otal
Lawrence H. Schwartz
Laurent Dercle
Publikationsdatum
12.04.2019
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 7/2019
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-01994-5

Weitere Artikel der Ausgabe 7/2019

Abdominal Radiology 7/2019 Zur Ausgabe

Classics in Abdominal Radiology

Fadeout sign of liver

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.